Literature DB >> 11275983

Molecular genetic alterations on chromosomes 11 and 22 in ependymomas.

K Lamszus1, L Lachenmayer, U Heinemann, L Kluwe, U Finckh, W Höppner, D Stavrou, R Fillbrandt, M Westphal.   

Abstract

Ependymomas arise from the ependymal cells at different locations throughout the brain and spinal cord. These tumors have a broad age distribution with a range from less than 1 year to more than 80 years. In some intramedullary spinal ependymomas, mutations in the neurofibromatosis 2 (NF2) gene and loss of heterozygosity (LOH) on chromosome arm 22q have been described. Cytogenetic studies have also identified alterations involving chromosome arm 11q, including rearrangements at 11q13, in ependymomas. We analyzed 21 intramedullary spinal, 14 ventricular, 11 filum terminale and 6 intracerebral ependymomas for mutations in the MEN1 gene, which is located at 11q13, and mutations in the NF2 gene, which is located at 22q12, as well as for LOH on 11q and 22q. NF2 mutations were found in 6 tumors, all of which were intramedullary spinal and all of which displayed LOH 22q. Allelic loss on 22q was found in 20 cases and was significantly more frequent in intramedullary spinal ependymomas than in tumors in other locations. LOH 11q was found in 7 patients and exhibited a highly significant inverse association with LOH 22q (p<0.001). A hemizygous MEN1 mutation was identified in 3 tumors, all of which were recurrences from the same patient. Interestingly, the initial tumor corresponded to WHO grade II and displayed LOH 11q but not yet a MEN1 mutation. In 2 subsequent recurrences, the tumor had progressed to anaplastic ependymoma (WHO grade III) and exhibited a nonsense mutation in exon 10 of MEN1 (W471X) in conjunction with LOH 11q. This suggests that loss of wild-type MEN1 may be involved in the malignant progression of a subset of ependymomas. To conclude, our findings provide evidence for different genetic pathways involved in ependymoma formation and progression, which may allow to define genetically and clinically distinct tumor entities. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275983     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1134>3.0.co;2-p

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 2.  Molecular genetics of pediatric central nervous system tumors.

Authors:  Nicole J Ullrich; Scott L Pomeroy
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

Review 3.  Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches.

Authors:  Chang-Hyun Lee; Chun Kee Chung; Chi Heon Kim
Journal:  Eur Spine J       Date:  2016-09-16       Impact factor: 3.134

4.  Intracranial ependymoma associated with multiple endocrine neoplasia type 1.

Authors:  A Al-Salameh; P François; S Giraud; A Calender; A-M Bergemer-Fouquet; L de Calan; P Goudet; P Lecomte
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

Review 5.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

6.  Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Authors:  Valentina Pirazzoli; Caroline Nebhan; Xiaoling Song; Anna Wurtz; Zenta Walther; Guoping Cai; Zhongming Zhao; Peilin Jia; Elisa de Stanchina; Erik M Shapiro; Molly Gale; Ruonan Yin; Leora Horn; David P Carbone; Philip J Stephens; Vincent Miller; Scott Gettinger; William Pao; Katerina Politi
Journal:  Cell Rep       Date:  2014-05-09       Impact factor: 9.423

Review 7.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 8.  Ependymoma in children: molecular considerations and therapeutic insights.

Authors:  J-H Kim; Y Huang; A S Griffin; P Rajappa; J P Greenfield
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

Review 9.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

Review 10.  The genetic and epigenetic basis of ependymoma.

Authors:  Stephen C Mack; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2009-06-18       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.